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ABSTRACT
OBJECTIVE: To determine health care costs and economic burden of 
epidemiological changes in diseases related to tobacco consumption.
METHODS: A time-series analysis in Mexico (1994–2005) was carried out 
on seven health interventions: chronic obstructive pulmonary diseases, lung 
cancer with and without surgical intervention, asthma in smokers and non-
smokers, full treatment course with nicotine gum, and full treatment course 
with nicotine patch. According with Box-Jenkins methodology, probabilistic 
models were developed to forecast the expected changes in the epidemiologic 
profi le and the expected changes in health care services required for selected 
interventions. Health care costs were estimated following the instrumentation 
methods and validated with consensus technique.
RESULTS: A comparison of the economic impact in 2006 vs. 2008 showed 
20–90% increase in expected cases depending on the disease (p<0.05), and 
25–93% increase in fi nancial requirements (p<0.01). The study data suggest that 
changes in the demand for health services for patients with respiratory diseases 
related to tobacco consumption will continue showing an increasing trend.
CONCLUSIONS: In economic terms, the growing number of cases expected 
during the study period indicates a process of internal competition and adds an 
element of intrinsic competition in the management of preventive and curative 
interventions. The study results support the assumption that if preventive 
programs remain unchanged, the increasing demands for curative health care 
may cause great fi nancial and management challenges to the health care system 
of middle-income countries like Mexico.
KEY WORDS: Smoking, epidemiology. Smoking, trends. Health 
care costs. Health expenditures. Time series studies. Mexico. Models, 
statistical.
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RESUMO
OBJETIVO: Avaliar os custos da atenção médica a doenças associadas ao 
tabagismo e o impacto econômico das mudanças epidemiológicas.
MÉTODOS: Análise de série temporal no México (1994-2005) de sete 
intervenções médicas em relação a: doença pulmonar obstrutiva crônica, 
câncer de pulmão com e sem intervenção cirúrgica, asma bronquial em 
fumantes e não-fumantes, tratamento com adesivos para deixar de fumar, 
tratamento com goma de mascar. As mudanças epidemiológicas esperadas 
e as necessidades fi nanceiras para atender a demanda de serviços foram 
avaliadas pelos modelos probabilísticos de Box-Jenkins. Os custos foram 
determinados de acordo com método de instrumentação e a técnica de 
consenso.
RESULTADOS: A comparação do impacto das mudanças epidemiológicas 
previstas para 2006 e 2008 mostrou incremento de 20% a 90%, dependendo 
do tipo de intervenção. O incremento nos custos da atenção médica foi de 25% 
a 93%. Há indícios que a demanda de serviços de saúde para as intervenções 
investigadas continuarão aumentando.
CONCLUSÕES: Em termos econômicos, o aumento na quantidade de 
casos esperados refl etem um fenômeno de competição interna em relação 
ao uso dos recursos adicionais entre atividades de promoção e prevenção da 
saúde relacionada ao tabagismo. Se não houver mudanças nos programas de 
prevenção, haverão desafi os econômicos de alto impacto no fi nanciamento 
dos sistemas de saúde.
DESCRITORES: Tabagismo, epidemiologia. Tabagismo, tendências. 
Custos de cuidados de saúde. Gastos em saúde. Estudos de séries 
temporais. México. Modelos estatísticos.
Major advances in medicine and technology have been 
associated with escalating expenditure on health since 
the 1960s. All countries are facing fi scal constraints in 
health care. As the limits of medicine and how political 
and economic forces shape health care are increasingly 
recognized, it becomes necessary to question personal 
and social meanings of illness and what it means to 
seek help from health systems, communities and from 
those empowered to provide health care.1,2
In this context, interest in the costs of cigarette smoking 
for health care derives from the need to identify the eco-
nomic burden that smoking imposes on a society in the 
perspective of epidemiological transition.4,8 According 
to the World Health Organization, worldwide mortality 
from tobacco is likely to rise from about four million 
deaths a year in 1998 to about 10 million a year in 2030. 
In other words, tobacco will cause about 150 million 
deaths in the fi rst quarter of the century and 300 million 
in the second quarter. The same report concludes that 
half of these deaths will occur in the 35–69 years age 
group, including many in productive middle age, with 
an average loss of 20–25 years of life.7,18
Smoking is the main preventable risk factor particularly 
for non-communicable diseases, namely lung cancer 
and a number of cardiovascular and respiratory dis-
eases. The smoking epidemic varies among countries. 
In developed countries, cardiovascular disease is the 
most common smoking-related cause of death. To-
bacco-related cancer comprises 16% of the total annual 
incidence of cancer cases in developed countries, while 
the corresponding rate in developing countries is 10%.4,5 
In China, smoking causes far more deaths from chronic 
respiratory diseases than from cardiovascular disease.3 
In Mexico, according to offi cial data, approximately 
40,000 persons per year die from smoking-related re-
spiratory diseases, and approximately 100,000 patients 
demand health care services to treat these illnesses.14
The economic impact of the smoking epidemic and their 
implications on the recent changes in resource alloca-
tion methods and practices in health care raise several 
dilemmas for policy and decision makers, particularly 
in the context of health care reform.6,* First, the double 
burden of communicable and non-communicable dis-
eases in transition countries: and the ever wider variety 
INTRODUCTION
* Health System Research. National Institute of Public Health. Project: costs and fi nancing consequences from changes in epidemiological 
profi le. 1995-2005. Final technical report. Cuernavaca, México: 2006: 23-48.
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of possible medical interventions increase health care 
costs and impose an ever greater burden on national 
and state budgets, thus hindering the effectiveness of 
cost-containment efforts.13 Second, the demand for 
health care, and the equity for resource allocation are 
greater and more diverse than ever before, especially 
in middle-income countries.12,*
Further, the burden of smoking-related illness is ex-
pected to increase the demand for costly treatment 
alternatives, which will compete with other demands 
for scarce resources. Therefore, there is a need to esti-
mate the true costs of smoking-related illness in order 
to evaluate the economic impact on the health care 
system.15 In this sense, the objective of the present study 
was to assess health care costs and economic burden 
of epidemiological changes in tobacco-related diseases 
focusing on respiratory diseases.
METHODS
A time-series analysis was carried out in Mexico. 
There were assessed annual health care costs of chronic 
obstructive pulmonary disease (COPD); lung cancer; 
asthma in non-smokers and smokers per case (or per 
year); and full treatment course with nicotine gum and 
nicotine patch. Secondly, it was also sought to describe 
the fi nancial consequences of changes in the epidemio-
logical profi le of these diseases and treatments.
Specialists were interviewed to determine the case man-
agement, which are all the diagnostic and therapeutic 
actions taken for the condition under study. In regard 
to COPD, lung cancer, non-smokers and smokers with 
asthma, defi nitions relied on case management prac-
tices in secondary and tertiary health care. For the full 
treatment course with nicotine gum and nicotine patch, 
primary health care was considered as the appropriate 
level. The defi nition of case management for each dis-
ease took into consideration the natural history of the 
disease, demand for health care, results from the review 
of clinical records, and clinical (epidemiologists) and 
administrative expert consensus.
In order to identify data on unitary costs of health 
inputs, interviews were conducted with experts in 
case management of each intervention: seven medical 
doctors, seven managers/economists, and seven epide-
miologists. The information these experts reported was 
complemented with data on procurement.
The case management included all inputs and produc-
tion functions required to meet all care requirements 
for each intervention or disease. In order to determine 
procedures and inputs in case management for cost 
containment, the methodology for classifying hospital 
patients and case management was followed, as well 
as the instrumentation technique.11,*
Nine data collection forms were designed to record 
the different processes, procedures and resources 
(production and input functions). They included dif-
ferent categories of analysis such as: infrastructure; 
human resources in physician hours, nurses’ hours 
and administrative personnel hours; laboratory studies; 
complementary studies; average number of bed days; 
components of the medicinal curative therapy; compo-
nents of intensive therapy; contracted services; general 
services; and other resources, processes, procedures 
and observations.
Once the production functions (medical consultations, 
drugs, emergency room care, hospitalization, labora-
tory studies, and others) required to the average case 
management were determined, this information was 
then compared to that collected from clinical records 
of the diseases to complement and/or validate the in-
formation provided by the experts. The clinical records 
were obtained from databases of Mexican Ministry of 
Health national reference hospitals; for each interven-
tion, a sample was studied with 10% of cases in an 
annual period.
To determine health costs three databases of health 
care costs in the public sector of Mexico were used.* 
These databases are representative of national reference 
hospitals and of relative costs of chronic respiratory dis-
eases. The costs of the following production functions 
were identifi ed based on the review of costs of a bed 
day; intermediate therapy; emergencies and intensive 
care; laboratory studies; hours of operating room usage; 
and inputs involved in events to be priced. After hav-
ing obtained unit costs for each process or procedure, 
numerical estimates were made using a calculation 
sheet. Depending on the amount of each measurement 
unit used per patient case, it was possible to obtain the 
total cost of each resource, process or procedure, and 
similarly, to calculate the total average cost of the case 
management.
To forecast future fi nancial consequences and economic 
impact, the estimation of the demand for health care 
was made on the basis of the demand experience at a 
national public referral hospital for respiratory diseases. 
Offi cial statistics were used for information, and a 
database was constructed to gather monthly morbidity 
and utilization trends from 1994 to 2005. Four proba-
bilistic models were developed to determine expected 
cases from 2006 to 2008, using mainly Box-Jenkins 
time-series analysis and the Stat Graphics statisti-
cal software program.9 Variables analyzed included 
changes of morbidity rates for the period and changes 
* Health System Research. National Institute of Public Health. Project: costs and fi nancing consequences from changes in epidemiological 
profi le. 1995-2005. Final technical report. Cuernavaca, México: 2006: 23-48.
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postural drainage for secretions. Annual follow-up: six 
medical visits at the primary care level; two medical 
visits at the secondary care level, including one X-ray, 
fi ve gasometries, four white blood cell counts and fi ve 
pulmonary function tests.
For lung cancer, the annual average case management 
without complications was outpatient case management 
without complications. An initial medical visit, 12 
follow-up visits with secondary care specialist and six 
referrals to tertiary care specialist. Diagnostic exams: 
one sputum cytology, one bronchoscopic biopsy and 
two X-rays. Surgical intervention, ten hospital days 
(pre- and post-surgery) and 15 radiotherapy sessions. 
Follow-up: outpatient drug treatment with cyclophos-
phamide doxyrubicine and CCNU (lomustine). Tests: 
12 X-rays and two sputum cytology.
Annual average case management of bronchial asthma 
for non-smokers was defi ned as two acute crises per 
year: an initial medical visit in a secondary care facility, 
four secondary care referrals, three annual follow-up 
medical consultations, two days of emergency room 
care. Outpatient drug treatment: corticosteroids, anti-
histaminics. Follow-up: three laboratory studies, one 
X-ray, and maintenance treatment.
Case management for bronchial asthma for smokers 
followed the same annual case management as for bron-
chial asthma for non-smokers, except for: four hospital 
stays, one medical consultation at tertiary care level, 
two X-rays, and three more laboratory studies.
For low birth weight babies, annual average case man-
agement without complications was defi ned as an initial 
medical visit, 18 follow-up visits with secondary care 
specialist. Medical diagnostic exams: white blood cell 
count, blood chemistry, serum electrolytes (calcium and 
iron), stool culture, blood proteins (two), and urinalysis 
(two). Therapy: food supplements for one year.
Annual average case management of full treatment 
course with nicotine gum without complications was 
defi ned as: outpatient case management without com-
plications at primary care level. An initial medical 
visit; 11 follow-up visits; ten group meetings of special 
therapy during the fi rst month of treatment and three 
gums per day for two months.
For full treatment course with nicotine patch, the an-
nual average case management without complications 
was defi ned as: outpatient case management without 
complications at primary care level. An initial medical 
visit; 11 follow-up visits; ten group meetings of special 
therapy during the fi rst month of treatment and one 
patch per day for one month.
in health policies and programs for the four diseases. 
The following steps were taken in the development of 
the probabilistic models:
1. Using observed cases from recent years, proba-
bilistic models were identified and developed. 
Determining variables for each disease were also 
identifi ed. Then the quality of the information was 
revised and the self-correlation coeffi cient among 
the observed cases was calculated in order to de-
termine the validity of the data. The last ten years 
were considered the valid period for the analysis.
2. Once the model was identified, the number of 
expected cases for each disease for the 2006–2008 
period was estimated. The trends of expected 
results were compared to results observed during 
the last ten years so that a similar behavior would 
be guaranteed in the disease’s risk factors as well 
as in health programs to respiratory diseases.
3. To determine a better adjustment of each model and 
of estimated cases, it was applied the Box-Pierce 
Chi-square. Finally, the most adequate model was 
defined, dividing the economic analysis 1. i n t o 
direct and indirect costs.
The number of cases was projected for a three-year 
period, using a 95% confi dence interval. According to 
evidence in other studies,15,16,** expert consensus and 
data from the National Survey of Chronic Disease* 
were used to identify the proportion of selected diseases 
attributable to smoking.
Once case management costs and the number of ex-
pected cases for each projected year were estimated, 
data processing was carried out using a spreadsheet to 
compute the case management cost for each selected 
disease. The fi nancial consequences of expected epi-
demiologic changes were then determined by means of 
an econometric adjustment factor to control for future 
infl ation rates.
RESULTS
Regarding the defi nition of case management for each 
intervention, results were as follows:
COPD was defi ned as annual outpatient case manage-
ment without complications (without information sug-
gestive of respiratory failure or infections). First medi-
cal visit, diagnostic tests (X-rays, electrocardiography, 
pulmonary function test, arterial gasometry, white blood 
cell count, blood chemistry, throat secretion swabbing). 
Outpatient drug treatment (bronchodilators, glucocor-
ticoids and mucolytic for 10 days). Three sessions of 
* Secretaria de Salud, Encuesta Nacional de Enfermedades Crónicas. Sistema Nacional de Salud. Factores de riesgo en daños a la salud. 
México DF. 2003.
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The average cost of treatment per patient was deter-
mined according to the defi nition of case management 
identifi ed by experts and validated with data from clini-
cal fi les. Only in the case of lung cancer was necessary 
to differentiate between the cost of case management 
with or without surgical intervention. This was because 
approximately 50% of patients with lung cancer in 
Mexico require surgical intervention in addition to 
drug therapy and radiotherapy. Case management direct 
economic costs were measured using as a reference the 
costs of inputs and salaries as of January 2006. Aver-
age costs for each disease or intervention are shown 
in Table 1.
The results of the proportion of disease attributable to 
smoking were: 80% in total cases of COPD, 25% in 
total cases of cardiovascular diseases, and 85% in total 
cases of lung cancer (Table 2). Data on asthma refer 
to the expected asthma cases associated with tobacco 
consumption, as described in the Methods section.
The four selected diseases showed signifi cant increase 
in fi nancial resources required to provide health care 
services, particularly in the case of COPD and lung 
cancer, since infl ation rates add up to the increase in 
the number of expected cases (Table 3).
DISCUSSION
Although conducted only in Mexico, the fi ndings of the 
present study related to trends in costs, epidemiological 
changes, health systems, and fi nancial consequences of 
respiratory diseases related to tobacco consumption are 
similar in most Latin American countries.17,19 Therefore, 
global and qualitative fi ndings can be used to address 
the health policy, planning and fi nancing process in 
view of the economic impact of these diseases in any 
Latin American country and particularly in middle-
income countries of the region.
In fact, part of the usefulness of the results for these 
countries is that general tendencies of economic and 
epidemiological fi ndings may be taken as references, 
but not the specifi c data. Therefore, the number of ex-
pected cases and the cost of case management are only 
applicable to Mexico, but the tendencies in incremental 
rates, in epidemiological terms as well as in terms of 
economic impact, would be similar in middle-income 
Latin American countries.
The results of the case management costs of the pres-
ent study are applicable only to the public health care 
system run by the government, which is currently the 
Table 1. Average costs (in US$) of case management in the 
public health sector. Mexico, 1994–2005.
Disease/intervention
Cost of case 
management
Chronic obstructive pulmonary disease 370.00
Lung cancer per year
(without surgical intervention)
730.00
Lung cancer per year
(with surgical intervention)
1,920.00
Non-smokers with asthma per year 811.00
Smokers with asthma per year 987.00
The cost of full treatment course with 
nicotine gum
193.00
The cost of full treatment course with 
nicotine patch
224.00
Exchange rate (January 2006): 10.60 Mexican $ per 1 US$.
Table 2. Number of cases expected per year, according to disease in a national public referral hospital. Mexico, 2006–2008.
Disease 2006 2007 2008 p-value
N (95% CI)
Chronic obstructive pulmonary disease 235 (218–252) 267 (248–286) 304 (284–324) <0.05
Asthma 1,840 (1,792–1,888) 1,906 (1,854–1,958) 2,165 (2,110–2,220) <0.01
Lung cancer 883 (848–918) 967 (927–1,007) 1,013 (968–1,058) <0.05
Full treatment course with nicotine gum 520 (513–527) 708 (699–717) 995 (984–1,006) <0.001
Table 3. Cost (in US$) expected per year for management of a disease in a national referral public hospital. Mexico, 2006–
2008.
Disease 2006 2007 2008
Chronic obstructive pulmonary disease 69,520.00 79,032.00 89,984.00
Asthma 454,020.00 470,305.00 509,538.00
Lung cancer 1,441,056.00 1,578,144.00 1,653,216.00
Full treatment course with nicotine gum 100,360.00 136,644.00 192,035.00
Exchange rate (January 2006): 10.60 Mexican $ per 1 US$.
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main source of health care in Mexico. Costs in the 
private health care sector would be higher because of 
higher costs of provider input. The economic evaluation 
method used in the present study implicitly included as 
a variable the quality of care provided by these services. 
This is relevant because in terms of economic evalu-
ation, results and their utilization are in doubt when a 
minimal quality of care is not controlled.
With regard to the economic impact and fi nancial 
consequences of tobacco consumption on the health 
care system, the cost results of this study indicate that 
it is important to limit the relative risk of smoking for 
the interventions to be studied. Then it will be valid to 
quantify the economic weight of health risks caused 
by smoking. Other interventions are associated with 
other risk factors, where smoking is just one element 
that leads to the demand for care, and in several cases, 
it is not the most important.
On the other hand, there is an internal competition for 
resources generated by changes in the epidemiologic 
profi le. It is noteworthy the hypothesis that costs and 
fi nancial consequences of changes in the epidemiologic 
profi le has two elements to be considered for future 
health policies. These are particularly preventive and 
curative health care programs for each selected disease, 
even if health resource allocation increases.
Results support the conclusion that if health care pro-
grams and risk factors for each selected disease remain 
unchanged for the next three years, the demand for 
health services will show an upward trend in all cases. 
Inaction by the government in health prevention and 
promotion regarding this study’s fi ndings will have 
fi nancial consequences for resource allocation decision 
making. A greater impact can be expected at the time of 
fi nancial resource allocation to meet the demands for 
medical care, considering the internal competition for 
service production inputs.
The information presented, particularly the estimation 
of the amounts and costs of critical inputs and expected 
cases of disease, is an indispensable tool for decision 
making in health policy strategic planning directed at 
covering the expected increase in demand caused by the 
study diseases in the coming years. In terms of health 
policy, the results of the present study may be used at 
three levels: health economic research, training of hu-
man resources, and producing and fi nancing of health 
care services to meet the demand for health services 
related to tobacco consumption.
Expected changes in the epidemiologic profi le will 
produce a demand for fi nancial resources which will 
overwhelm allocated resources, especially if health care 
expenditure trends in past years are considered. Another 
important consequence is that the internal competition 
for fi nancial resources was seen. For example, the fi -
nancial resources required to meet the demand for lung 
cancer compete with resources required for nicotine 
gum treatment to stop smoking. This situation is more 
complicated because the cost of services for 20% of 
expected lung cancer cases is equivalent to what it 
would cost to meet 100% of the demand for nicotine 
gum treatment to stop smoking. A similar situation is 
observed when analyzing the fi nancial amounts within 
each selected disease, comparing hospital versus out-
patient case management costs.
As for the results validity, it is problematic to undertake 
a comparative analysis of validity across countries. 
For example, when comparing the results of health 
care costs for lung cancer in middle-income countries, 
the results in the present study were similar to those 
reported by a World Bank study developed in 199310 
(US$ 1,367.00 per case management in adult patients 
aged 55–60 years). However, the methodology used 
to determine the costs of case management was differ-
ent, as it considered the case management applicable 
to all adult patients, not only those 55–60 years of 
age. Thus, the importance of specifying the method of 
analysis used and the inputs and production functions 
that were included in the average cost calculation for 
comparability.
The present fi ndings could be included in cost-benefi t 
and cost-effectiveness analyses of intervention alterna-
tives for each selected disease in health research poli-
cies. The results could help policymakers in identifying 
mechanisms and amounts to invest in prevention, cura-
tive or rehabilitation activities. On the other hand, con-
sidering that this was an evaluative forecasting study, 
it would be advisable to monitor the costs of health 
services and carry out an annual analysis of the costs 
of epidemiologic profi le changes in order to compare 
the projected fi ndings with real life situations. Such 
a comparison would provide greater methodological 
support to extend the application of cost-monitoring 
systems to other diseases, or to overturn the structure 
and design of the methods. In long-term projection, 
data used in probabilistic models should be periodi-
cally updated (every two years) so that projections are 
also updated four years ahead of the year of update. 
It is recommended that the period not extend beyond 
fi ve years since the confi dence intervals would then 
be questionable.
In conclusion, the present study provided basis for 
identifying the fi nancial consequences of health priori-
ties in demands related to tobacco consumption in the 
short, medium and long term. Similar approaches could 
be used as a decision making tool in matters of health 
services production for specifi c demands, but above 
all in matters of health services fi nancing. Financial 
allocation mechanisms may be designed based on these 
studies. Tax policy instruments may also be justifi ed and 
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negotiated in order to direct more fi nancial resources 
towards health services based on an increase in taxes 
on cigarettes. This increase would necessarily have to 
be directly proportional to the fi nancial consequences 
on the health system due to the demand for services 
related to tobacco consumption.
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